{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:23:46Z","timestamp":1791995026242,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ejca.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T18:02:58Z","timestamp":1588528978000},"page":"168-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature"],"prefix":"10.1016","volume":"132","author":[{"given":"Jacob","family":"Zaemes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2020.03.015_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.ejca.2020.03.015_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/cid\/ciw838","article-title":"Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis","volume":"64","author":"Cheng","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ejca.2020.03.015_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00157-2017","article-title":"Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis","volume":"50","author":"Dobler","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ejca.2020.03.015_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2016.11046","article-title":"Screening for latent tuberculosis infection in adults: US preventive Services Task Force recommendation statement","volume":"316","year":"2016","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ejca.2020.03.015_bib5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.4049\/jimmunol.1003304","article-title":"CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition","volume":"186","author":"Barber","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2020.03.015_bib6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/1759-7714.13057","article-title":"Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer","volume":"10","author":"Kuo","year":"2019","journal-title":"Thorac Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.015_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-019-0636-7","article-title":"Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials","volume":"7","author":"Lv","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2020.03.015_bib8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2020.03.015_bib9","first-page":"289","article-title":"Tuberculosis: case report","volume":"1686","author":"Sharon","year":"2018","journal-title":"Reactions"},{"key":"10.1016\/j.ejca.2020.03.015_bib10","series-title":"Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC)","author":"Rapoport","year":"2017"},{"issue":"Supplement_5","key":"10.1016\/j.ejca.2020.03.015_bib11","first-page":"mdz253","article-title":"1268P A phase Ia\/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumours or lymphomas","volume":"30","author":"Shen","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2020.03.015_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2020.03.015_bib13","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.03.015_bib14","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti\u2013PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.03.015_bib15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/0284186X.2018.1433877","article-title":"Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer","volume":"57","author":"Jensen","year":"2018","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2020.03.015_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ejca.2020.03.015_bib17","article-title":"Significant neutrophilic emperipolesis in squamous cell carcinoma","volume":"2018","author":"Tetikkurt","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ejca.2020.03.015_bib18","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.2147\/OTT.S178246","article-title":"Activated pulmonary tuberculosis in a patient with melanoma during pD-1 inhibition: a case report","volume":"11","author":"He","year":"2018","journal-title":"OncoTargets Ther"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.015_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2019","journal-title":"J Infect Chemother"},{"issue":"475","key":"10.1016\/j.ejca.2020.03.015_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.015_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/qjmed\/hcy243","article-title":"Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment","volume":"112","author":"Tsai","year":"2019","journal-title":"QJM Int J Med"},{"key":"10.1016\/j.ejca.2020.03.015_bib22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with Nivolumab for Non-small cell lung cancer: case report and literature review","volume":"9","author":"van Eeden","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2020.03.015_bib23","first-page":"1","article-title":"Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases","author":"Inthasot","year":"2019","journal-title":"Acta Clin Belg"},{"issue":"11","key":"10.1016\/j.ejca.2020.03.015_bib24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ejca.2020.03.015_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.1995","article-title":"A case of toxic hepatic event occurring in combination treatment with nivolumab and anti-tuberculosis in advanced lung cancer","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"30","key":"10.1016\/j.ejca.2020.03.015_bib26","doi-asserted-by":"crossref","first-page":"13402","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)\u2013deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"L\u00e1z\u00e1r-Moln\u00e1r","year":"2010","journal-title":"Proc Natl Acad Sci Unit States Am"},{"issue":"5","key":"10.1016\/j.ejca.2020.03.015_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T cell-derived IFN-\u03b3 plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PLoS Pathog"},{"issue":"19","key":"10.1016\/j.ejca.2020.03.015_bib28","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1158\/1078-0432.CCR-16-0663","article-title":"FDA approval summary: accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma","volume":"23","author":"Chuk","year":"2017","journal-title":"Clin Canc Res"},{"issue":"14","key":"10.1016\/j.ejca.2020.03.015_bib29","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin Canc Res"},{"issue":"20","key":"10.1016\/j.ejca.2020.03.015_bib30","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1800762","article-title":"Prednisone for the prevention of paradoxical tuberculosis-associated IRIS","volume":"379","author":"Meintjes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.03.015_bib31","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Ferrara","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2020.03.015_bib32","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.015_bib33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3947\/ic.2013.45.1.44","article-title":"Indeterminate T-SPOT. TB test results in patients with suspected extrapulmonary tuberculosis in routine clinical practice","volume":"45","author":"Lee","year":"2013","journal-title":"Infec Chemother"},{"key":"10.1016\/j.ejca.2020.03.015_bib34","series-title":"FRI0140 restarting biologics in patients who developed tuberculosis during anti TNF-alpha treatment","author":"Ozguler","year":"2015"},{"issue":"4","key":"10.1016\/j.ejca.2020.03.015_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153816","article-title":"Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean society of spondyloarthritis research","volume":"11","author":"Kim","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ejca.2020.03.015_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ecco-jcc\/jjv172","article-title":"Reintroduction of anti-TNF\u03b1 therapy after (or even during) anti-TNF\u03b1-associated tuberculosis in immune-mediated diseases","volume":"10","author":"Abreu","year":"2016","journal-title":"J Crohn's Colitis"},{"issue":"9","key":"10.1016\/j.ejca.2020.03.015_bib37","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920301568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:28:13Z","timestamp":1760732893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920301568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":37,"alternative-id":["S0959804920301568"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.03.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}